-+ 0.00%
-+ 0.00%
-+ 0.00%

Sagimet Biosciences prices 29,166,700-share offering at $6, raising $175 million

PUBT·04/27/2026 11:15:46
Listen to the news
Sagimet Biosciences prices 29,166,700-share offering at $6, raising $175 million
  • Sagimet Biosciences priced underwritten follow-on offering of 29,166,700 shares of Series A common stock at USD 6 per share.
  • Gross proceeds expected at about USD 175 million.
  • Closing expected on or about April 28, 2026.
  • Net proceeds earmarked for Phase 3 denifanstat acne trial, TVB-3567 through Phase 2 topline results, topical FASN inhibitor to IND submission.
  • Cash runway expected to fund acne programs through 2028, including planned Phase 3 readout in moderate to severe acne.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270715PRIMZONEFULLFEED9707425) on April 27, 2026, and is solely responsible for the information contained therein.